What is ALS Phase 3 Study Dexpramipexole (KNS-760704)?
CATEGORY:
NCT01281189 is a randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of dexpramipexole in subjects with amyotrophic lateral sclerosis (ALS). Dexpramipexole was previously known as KNS-760704. Other study IDs: EMPOWER, 223AS302, EUDRA CT NO:2010-022818-19.
Save up to 80% off your prescriptions!
How do members experience ALS Phase 3 Study Dexpramipexole (KNS-760704)?
Top 5 reported purposes & perceived effectiveness
Purpose | Patients | Evaluations | Perceived Effectiveness |
---|---|---|---|
Amyotrophic lateral sclerosis | 37 | 95 | |
Participate in clinical trial | 17 | 21 | |
Increase effect of another treatment | 2 | 14 | |
Arthritis pain in shoulder joints | 1 | 0 |
Common side effects
Side effect | Patients | Percentage |
---|---|---|
Nausea | 3 | |
Heartburn | 2 | |
Insomnia | 2 | |
Neutropenia (low neutrophils) | 2 | |
Oily facial skin | 2 | |
Burning sensation in eyes | 1 |
Side effect severity
Severity | Evaluations | Percentage |
---|---|---|
Severe | 4 | |
Moderate | 4 | |
Mild | 28 | |
None | 65 |
Member evaluations
AustinMJ
evaluated on Jan 16, 2013
- Perceived effectiveness for amyotrophic lateral sclerosis: Can't tell
- Side effects: None
r
Root10996
evaluated on Oct 10, 2012
- Perceived effectiveness for Participate in clinical trial: Can't tell
- Side effects: None
fki2001
evaluated on Oct 11, 2012
- Perceived effectiveness for Participate in clinical trial: Can't tell
- Side effects: None
Learn more about our community’s experience with ALS Phase 3 Study Dexpramipexole (KNS-760704)
What are people saying about ALS Phase 3 Study Dexpramipexole (KNS-760704)?
70
70
members have reported taking ALS Phase 3 Study Dexpramipexole (KNS-760704)
Join the conversation and connect with people who have taken ALS Phase 3 Study Dexpramipexole (KNS-760704)
Last updated: